A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.
靶向钍-227偶联物在获得性耐药的临床前模型中显示出疗效，并具有与化疗药物和抗血管生成疗法联合应用的潜力
期刊:Molecular Cancer Therapeutics
影响因子:5.5
doi:10.1158/1535-7163.MCT-22-0808
Zitzmann-Kolbe Sabine, Kristian Alexander, Zopf Dieter, Kamfenkel Claudia, Politz Oliver, Ellingsen Christine, Hilbig Jochen, Juul Mark U, Fonslet Jesper, Nielsen Carsten H, Schatz Christoph A, Bjerke Roger M, Cuthbertson Alan S, Mumberg Dominik, Hagemann Urs B
